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a b s t r a c tThe mode of action of rabbit antithymocyte globulin (rATG) includes preferential inhibition of pre-existing
donor-reactive memory T-cell reconstitution and possibly apoptosis of plasma cells, the source of donor speciﬁc
antibodies (DSAs). In kidney transplant patients with low-strength preformed DSAs, non-comparative data have
shown a low incidence of antibody-mediated rejection (ABMR) and graft survival using rATG even without de-
sensitization procedures. For high strengths of preformed DSAs, rATG induction with more aggressive desensiti-
zation appears effective, with mixed results concerning the addition of B-cell speciﬁc agents. Regarding
production of de novo DSA (dnDSA), interpretation of retrospective analyses is limited by selective use of rATG
in higher-risk patients. Observational data in moderately sensitized kidney transplant patients suggest that the
incidence of dnDSA and ABMR is signiﬁcantly lower with rATG versus basiliximab. A randomized pilot study
has suggested that addition of rituximab or bortezomib may not further inhibit dnDSA production in rATG-
treated patients. Overall, rATG appears to inhibit DSA production, with a potential role in reducing the risk of
ABMR in kidney transplant patients with high-strength preformed DSA, or lowering dnDSA inmoderately sensi-
tized patients. Randomized trials are awaited.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The poor prognosis associated with anti-human leukocyte antigen
(HLA) donor-speciﬁc antibodies (DSAs) following kidney transplanta-
tion is well-established. Preformed class I and II DSAs, in particular, con-
fer a marked increase in the risk of antibody-mediated rejection
(ABMR) [1–3] and reduced allograft survival [1,2,4,5], even when the
titer is below the threshold for a positive crossmatch, whereas
preformed complement (C1q)-ﬁxing DSAs show a less convincing asso-
ciationwith poor outcomes [6,7]. Development of de novoDSA (dnDSA)
after kidney transplantation also incurs a higher risk for acute rejection
[8,9], chronic ABMR [10] and graft survival [4,10,11]. Complement-
binding dnDSAs show a particularly strong association with ABMR and
graft failure, increasing the risk of graft loss by over four-fold [10].
Rates of acute T-cell mediated rejection (TCMR) and ABMR are both
higher in kidney transplant patients who develop dnDSA compared to
recipients with preformed DSA [12], and the combination of ‘mixed’
TCMR and ABMR is especially unfavorable. Of note, donor-speciﬁcity⁎ Corresponding author at: Department of Nephrology, Hospital del Mar, Passeig
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donor-speciﬁc appear to be less relevant [1].
There is no conclusive evidence to conﬁrm that any immunosup-
pressive regimen or agent prevents or delays DSA production. However,
randomized clinical trials, undertaken before routine DSA monitoring
was adopted, have pointed to a possible effect for rabbit antithymocyte
globulin (rATG) induction. Randomized studies have shown rATG to be
effective in preventing biopsy-proven acute rejection (BPAR), and spe-
ciﬁcally, steroid-resistant BPAR, in kidney transplant patients catego-
rized as sensitized based on anti-HLA panel reactive antibody (PRA)
status or other established risk factors [13–15]. An early trial of 89 pa-
tients with PRA in the range 5%–100%, with or without positive
complement-dependent cytotoxicity (CDC) B-cell crossmatch, showed
that compared to no induction, rATG induction signiﬁcantly reduced
BPAR and increased one-year graft survival and function, even at the
highest levels of sensitization (PRA N80%) [15]. Rates of ABMR were
not reported. More recently, a randomized trial comparing rATG induc-
tion versus the interleukin 2 receptor antagonist (IL-2RA) daclizumab in
227 HLA-sensitized kidney transplant patients (current PRA ≥30% and/
or peak PRA ≥50%) receiving tacrolimus, mycophenolatemofetil (MMF)
and steroids as maintenance therapy showed a signiﬁcant reduction
rate of BPAR and steroid-resistant BPAR in the rATG-treated cohort at
one year [14]. There was no difference in the rate of ABMR (one casethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tients were given intravenous immunoglobulin (IVIG) and/or plasma-
pheresis (with another given OKT3), while in the daclizumab arm six
patients were given IVIG, plasmapheresis or rituximab, and a further
seven needed anti-rejection treatmentwith rATG. Brennan et al. also re-
ported a signiﬁcant beneﬁt for rATG versus IL-2RA induction in terms of
BPAR and steroid-resistant rejection in another cohort of kidney trans-
plant patients at increased risk for acute rejection or delayed graft func-
tion [13]. A systematic review with a meta-analysis has conﬁrmed that
when IL-2RA induction (basiliximab or daclizumab) is compared to
ATG (16 randomized controlled trials, 2211 participants), there is a ben-
eﬁt for ATG therapy over IL-2RA in terms of BPAR at one year, but at the
cost of an increase in malignancy and cytomegalovirus (CMV) disease
[16]. However, the meta-analysis included studies from the 1990s and
early 2000s when ATG doses were markedly higher than at present,
and also included several studies of equine ATG, so applicability to
rATG inductionwithmodern regimens is not certain.More recent regis-
try analyses have shown mixed ﬁndings in terms of risk for post-
transplant lymphoproliferative disease (PTLD) or malignancy, but
again can be difﬁcult to interpret since theywere not necessarily specif-
ic to rATG [17–20]. In the TAILOR registry of living-donor kidney trans-
plant recipients, 2322 patients transplanted in 2003–2008 and given a
mean cumulative rATG dose of ~5.3 mg/kg showed a PTLD incidence
of 0.9% at ﬁve years, comparable with the kidney transplant population
overall [20]. These data are a reminder that the overall intensity of im-
munosuppression should not be disproportionately increased, to avoid
a heightened risk of malignancies and infections.
While these trials do not provide direct evidence regarding an inﬂu-
ence of rATG on pre-existing DSA or the development of dnDSA, they do
suggest that use of rATG induction merits further exploration to exam-
ine the balance of beneﬁts and risks. The current data relating to rATG
(Thymoglobulin) and anti-HLA DSA are discussed here.
2. Themode of action for rATG: potential relevance to DSA production
ABMR is a progressive process, diagnosed based on the presence of
circulatingDSAwith speciﬁc histologic criteria (primarilymicrovascular
inﬂammation and transplant glomerulopathy) and immunohistologic
characteristics [21,22].
rATG interacts with a large range of antigens on immune and non-
immune cell types, inducing apoptosis of B-cells, peripheral T-cells and nat-
ural killer (NK) cells, and modulates leukocyte/endothelium interactions
[23–25]. Evidence from a murine model has shown that rATG targets pre-
existing donor-reactive memory T-cells, suppressing their recovery more
effectively than other components of the T-cell response [26]. In addition,
the well-documented phenomenon of preferential reconstitution of T-
regulatory cells (Tregs) after rATG treatment [27–29]may also be beneﬁcial.
rATGmay also exert a direct effect, since it contains antibodies against
several plasma cell antigens. In vitro studies by Zand et al. have shown
that rATG strongly induces apoptosis in terminally differentiated plasma
cells (CD138+) at clinically relevant concentrations (1–100 ng/mL) via a
complement-independent process [30] and may thus potentially inhibit
production of DSA, although this has not been demonstrated in these
studies. Other researchers, however, have observed no effect of rATG
(or rituximab or IVIG) on plasma cell apoptosis in vitro [31] or in vivo
after desensitizationwith rATG [32], although CD27+memory B-cells ap-
pear to be depleted [32].
Taken together, from the complex impact of rATG on blood cell con-
stituents, especially on theplasma and Treg compartment, it could be hy-
pothesized that rATG also affects DSA production post-transplant and
the risk for ABMR. However, this remains to be evaluated.
3. rATG in presensitized patients
Anti-HLA antibodies have been detected in 10%–24% of patients
prior to kidney transplantation [33–35], with estimates inﬂuenced bythe choice of techniques and the era of the study population. Organ
matching is challenging in broadly sensitized patients due to the high im-
munologic barrier. Even if transplantation is performed and crossmatches
are negative, presensitization with DSA predicts poor graft survival
[10,34,36–38]. Survival is especially low when DSAs persist [10] or in-
crease [39] post-transplant, due to higher rates of ABMR [36,39]. Known
risk factors for presensitization against HLA antigens include prior blood
transfusions [40,41], pregnancy [40], and previous surgery including
prior transplantation [42]. Infectious agents may also potentiate an anti-
HLA response as a result of molecular mimicry [43].
Desensitization protocols are complex, but the most widely used
downregulation strategies are plasmapheresis and/or IVIG, frequently
with intravenous administration of the chimeric monoclonal anti-
CD20 antibody rituximab. There has also been recent interest in the
plasma cell-targeted protease inhibitor bortezomib and the anti-
complement antibody eculizumab [44]. These regimens have accept-
able short-term graft survival, but rates of acute rejection and ABMR re-
main much higher than in non-sensitized patients [45]. Encouragingly,
however, a large cohort study of 211 live donor kidney recipients re-
ported a signiﬁcant survival beneﬁt following desensitization versus re-
maining on dialysis [46].
Numerous studies have reported outcomes usingdifferent precondi-
tioning regimens and rATG induction, as discussed below.With no con-
sensus regarding the optimal combination and doses of desensitizing
techniques, these studies describe a wide range of populations and
methodologies. No trial has compared outcomes following a precondi-
tioning regimen with or without the use of rATG induction, limiting an
accurate assessment of the speciﬁc contribution of rATG in any regimen.
3.1. Low-strength DSA
The risk of ABMR increases with DSA strength at the time of trans-
plantation [47]. Nevertheless, in candidates with low-strength DSA
(i.e. DSA detectable only on more sensitive assays such as ﬂow-
cytometric crossmatch or single antigen ﬂow beads), ABMR rates are
still higher than in DSA-negative patients despite relatively weak sensi-
tization.Without preconditioning, acute and chronic ABMRhas been re-
ported in 33% and 42% of these patients [48], although graft survival
rates are typically similar to patients with negative crossmatch [47].
No study has compared outcomes using rATG induction or no rATG in-
duction in kidney transplant patients with low-strength DSA. Two cen-
ters have described the results of desensitization in a population of
kidney transplant recipients with low-strength DSA who received
rATG induction, with no control regimen [49,50] (Table 1). Bächler
and colleagues prospectively identiﬁed the presence of low-strength
DSA by single antigen ﬂowbeads (‘virtual crossmatch’) in 37 candidates
(all with negative T-cell and B-cell CDC crossmatch) who received IVIG
prior to graft reperfusion and on days 1–4 (total dose 2 g/kg), with rATG
(using the Fresenius preparation, not Thymoglobulin®) 9mg/kg prior to
reperfusion and 3 mg/kg on days 1–4 [49]. Maintenance immunosup-
pression comprised tacrolimus, MMF and steroids. Compared to a co-
hort of 67 historical controls, also with low-strength DSA but without
additional treatmentwith IVIG or rATG (butwith IL-2 receptor blockade
in 48%), the rate of ABMR in clinically-indicated biopsies was markedly
lower six months after transplantation in the IVIG/rATG treatment
group (11% versus 46%, p= 0.0002). In addition, the rate of TCMR in in-
dication biopsies was also signiﬁcantly lower in the IVIG/rATG-treated
patients (0% versus 50%, p b 0.0001). Subclinical TCMR on protocol bi-
opsies at three and six months was also less frequent in the IVIG/rATG
cohort (11%–18% versus 43%–46%, p = 0.008–0.03) [49]. The rate of
subclinical ABMR did not differ between the groups. Akalin et al. identi-
ﬁed a subgroup of patients who were CDC crossmatch T-cell negative
but B-cell positive, or ﬂow cytometry crossmatch positive, and stratiﬁed
them according to DSA strength on single antigen ﬂow bead assay [57]
(Table 1). In the 12 patients with ‘weak or moderate’DSA strength, IVIG
with rATG induction (1.5 mg/kg/day for ﬁve days) and a regimen of
Table 1
rATG induction in patients receiving desensitizing regimens prior to kidney transplantation.
Study Design/
donor type
n Crossmatch
detection
method
Sub-groups Desensitization Induction/
maintenance
immuno-
suppression
Follow-up ABMR Graft
survival
Patient
survival
Low-strength DSA
Knight 2013
[51]
Retrospective
Living donor
44 CDC + ﬂow
cytometry
CDC XM-negative
FC XM-negative
None rATG
TAC
MMF
Steroids
Median
26 months
3.3% 100% –
CDC XM-negative
FC XM-positive
0% 100% –
Bächler
2010
[49]
Prospective
Historical controls
Deceased or
living donor
37
(+ 67
controls)
CDC + SAFB Prospective
cohort, SAFB
XM-positive
IVIG rATG
TAC
MMF
Steroids
Median
2 years
11% at
month 6
0% due
to
ABMR at
year 1
–
Controls, SAFB
XM-positive
None No rATG
Various
Median
8.5 years
46% at
month 6
(p = 0.0002)
7.5% due
to ABMR
at year 1
Roberti
2007
[52]
Retrospective
Pediatric patients
Living donor
50 CDC, ﬂow
cytometry,
SAFB
CDC XM-negative
FC XM-negative
SAFB XM-negative
None rATG
TAC
MMF
Steroids
3 years 0% 100% 96.7%
CDC XM-negative
FC XM-negative
SAFB XM-positive
Basiliximab
TAC
MMF
Steroids
3 years 0% 100% 91%
Thielke
2005
[50]
Retrospective
Living donors
16 CDC + ﬂow
cytometry
– PP
IVIG
rATG
TAC
MMF
Steroids
25% 100% 100%
High DSA
Zhang 2011
[53]
Retrospective
Living donor
14 CDC, ﬂow
cytometry,
SAFB
– PP
IVIG
± rituximab
rATG
TAC
MMF
Steroids
1 year 14.3% 92.9% 100%
Vo 2006
[54]
Retrospective
2 subgroups
(by induction
type)
Deceased or
living donor
97 CDC rATG induction
Daclizumab
induction
IVIG TAC
MMF
Steroids
2 years 21%a
22%a
90%a
84%a
100%a
96%a
Stegall 2006
[55]
3 subgroups
(by treatment)
61 CDC, ﬂow
cytometry,
SAFB
Sequential
desensitizing
protocols
PP
Low-dose IVIG
Rituximab
± splenectomy
rATG
TAC
MMF
Steroids
n/a 37% – –
High-dose IVIG 80% – –
PP
Low-dose IVIG
Rituximab
Pre-tx rATG (5 days)
+ Post-tx DSA
monitoring
29% – –
Various DSA levels
Mai 2009
[56]
Retrospective
3 subgroups
(by PRA)
Deceased or
living donor
94 Flow
cytometry
PRA b 20%,
FC-XM negative
none rATG
TAC
MMF
Steroids
3 years 1.7% 78.6% 90.6%
PRA N20%,
FC XM-negative
none 6.3% 80.4% 93.8%
PRA N20%,
FC XM-positive
IVIG 30.0% 88.7% 93.8%
Akalin 2008
[57]
Prospective
3 subgroups
(by DSA)
Living donors
35 CDC T-cell-
negative and
CDC B-cell-
positive or
FC-positive
Low/moderate
DSA
IVIG rATG
TAC
MMF
Steroids
Median
18
0% 100% 100%
High DSA IVIG 44% 78% 100%
High DSA IVIG + PP 7% 86% 93%
Low-strength DSA deﬁned as negative CDC crossmatch with DSA detectable by ﬂow cytometry or single-antigen ﬂow beads. High-strength DSA deﬁned as positive CDC T-cell or B-cell
crossmatch. CDC, complement-dependent cytotoxicity; DSA, donor-speciﬁc human leukocyte antibodies; FC, ﬂow cytometry; n/a, not available; IVIG, intravenous immunoglobulin;
MMF,mycophenolatemofetil; PP, plasmapheresis; rATG, rabbit antithymocyte globulin; SAFB, single-antigen ﬂowbeads; PRA, panel reactive antibodies; TAC, tacrolimus; XM, crossmatch.
a Fewer primary transplants (p b 0.002) and fewer patients achieving negative crossmatch (p b 0.03) by time of transplant in the rATG group versus the daclizumab group.
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though the absence of a control group means that strong conclusions
cannot be drawn. In contrast, other small retrospective studies compar-
ing patients with low-strength DSA versus a DSA-free control group
have suggested that ABMR and graft survival rates are similar even in
the absence of desensitization procedures when using rATG induction
with tacrolimus, MMF and steroids [51,52].3.2. High-strength DSA
Compared to patients with low-strength DSA, patients with high-
strength DSA are at signiﬁcantly greater risk of ABMR, as well as both
early and late graft loss [38,47]. Stegall and colleagues used rATG induc-
tion in 61 patients with CDC T-cell positive crossmatch [55] (Table 1).
The desensitization protocol evolved over the period of analysis, from
88 J. Pascual et al. / Transplantation Reviews 30 (2016) 85–91(i) plasmapheresis with low-dose IVIG and rituximab (with splenecto-
my in the early cases), to (ii) high-dose IVIG switching to the earlier reg-
imen for non-responders, then ﬁnally to (iii) plasmapheresis, low-dose
IVIG and rituximab with pre-transplant rATG. rATG (1.5 mg/kg/day)
was given after plasmapheresis on the ﬁrst ﬁve days of the precondi-
tioning regimenwith post-transplant DSAmonitoring and further inter-
vention was given as required to maintain a low DSA strength [55]. The
latter regimen, with rATG induction, achieved a lower rate of ABMR
than the early rituximab-containing protocol (29% versus 37%), al-
though follow-up times are not reported. One study, by Vo et al., has
compared rATG induction versus IL-2RA induction (daclizumab) in
two sequential cohorts of CDC crossmatch-positive patients who re-
ceived IVIG preconditioning [54]. In the earlier phase of this retrospec-
tive study, 58 patients received daclizumab; latterly, 39 patients were
given rATG induction. The incidence of ABMR by two years was similar
(daclizumab 21%, rATG 22%) [54]. Graft survival (84% and 90%, respec-
tively) and patient survival (96% and 100%, respectively) were not sig-
niﬁcantly different (Table 1), but more daclizumab-treated patients
were crossmatch-negative by the time of transplant (48% versus 25%,
p b 0.03), which is likely to have skewed the results [54]. Conﬁrmatory
trials are awaited.
Other centers have reported their experience with rATG induction
after use of various preconditioning protocols, allocated according to
the risk level of transplant candidates based on T-cell immunoglobulin
titers, positive T-cell and/or B-cell crossmatch by CDC, ﬂow cytometry,
ELISA or single antigen ﬂow bead assay [58–60]. Some reports have ad-
ministered rATG in an unidentiﬁed proportion of patients [46,60,61],
making it difﬁcult to identify the contribution of rATG. One randomized
trial in 40 kidney transplant patients has compared rATG alone
(9 mg/kg total dose) to rATG (6–7.5 mg/kg) with rituximab or with
bortezomib, or with both agents [62]. The study population, however,
included patients if they had high cytotoxic PRA levels or prior allograft
loss with more than one rejection, as well as patients with conﬁrmed
DSA by CDC or ﬂow cytometry, and no more than 6/10 patients in
each treatment group had a conﬁrmedpositive crossmatch or DSA. Nev-
ertheless, it is interesting that an increase in preformed DSA occurred in
no patients given rATG alone, but in up to 40% of patients in the other
groups. However, rATG with rituximab entirely prevented ABMR,
whereas one patient (10%) given rATG alone had ABMR and three pa-
tients (30%) given rATG and bortezomib had ABMR, one of whom lost
their graft as a result [62]. Addition of B-cell speciﬁc agents to rATG in-
duction may be effective, but these ﬁndings are inconclusive and trials
exclusively in recipients with pre-existing DSA are lacking. Moreover,
it should be noted that one retrospective study of 77 kidney transplant
patients given rituximab for various reasons showed a signiﬁcantly
higher rate of death from infectious causes than a control group of pa-
tients without rituximab therapy [63].
Overall, rATG induction for presensitized kidney transplant patients,
even with low-strength DSA, appears to be an appropriate adjunct to
the desensitization process. In patients with high strengths of pre-
transplantDSA, thepotential incremental beneﬁt of rATGwith addition-
al preconditioning strategies remains unclear, and no ﬁrm conclusions
can be drawn regarding the use of rATG in this setting.
4. De novo DSA
Little is known about the dominant risk factors for dnDSA. Two pro-
posed factors are poor HLA matching, particularly at the DQ locus
[11,64,65], and non-adherence to the immunosuppressive regimen
[66]. Younger patients (e.g. b50 years) are at increased risk [8,67], pos-
sibly due to a more robust immunological response and greater non-
adherence. African American recipients may also be prone to develop
dnDSA [64]. Recent studies have reported an incidence of 8%–11% by
the end of the ﬁrst year after kidney transplantation [68,69], rising as
high as 25% in patients at high immunological risk [62]. Although theo-
retically use of rATG induction therapy to inhibit activity of both T-cellsand B-cells in the immediate post-transplant periodwould seema ratio-
nal strategy to reduce early dnDSA production in at-risk individuals
[23], published data supporting this are particularly limited.
4.1. rATG induction and dnDSA production
Prospective data on the rate of dnDSA are available from a subpopu-
lation analysis of 37 kidney transplant patients taking part in a random-
ized trial assessing early corticosteroid withdrawal, all of whom
received rATG induction with tacrolimus and MMF maintenance thera-
py [70]. All patients showed a negative CDC crossmatch at baseline. An-
nual follow-up includedmixed bead antigen testing, with single antigen
ﬂowbead testing in thosewho tested positive. By year 5, only one of the
37 patients (2.7%) had developed dnDSA, but this low rate may have
reﬂected the study deﬁnition of dnDSA i.e. antibodies which developed
after the ﬁrst post-transplant year [70].
Retrospective analyses [4,8,12] have described the baseline charac-
teristics – including the type of induction therapy – in kidney transplant
patients who did or did not develop dnDSA during follow-up, but inter-
pretation is hampered by bias in the use of rATG induction. Huang et al.
administered rATG pre-transplant in all high-risk patients (deﬁned as
preformed DSA, African American recipients, retransplants, or PRA
N20%) and used basiliximab, rATG or no induction in low-risk patients
[12] (Table 2). The observation that there was no signiﬁcant difference
in rATG use in patients with or without dnDSA (Table 3) is largely un-
helpful given the selective nature of rATG administration (Table 3). Sim-
ilarly, Cooper et al. observed an identical proportion of rATG use in a
series of 244 patients who did or did not develop dnDSA by month 24
post-transplant, but rATG was again used preferentially in recipients
at higher immunologic risk [8]. Consistent with this, a retrospective
analysis of 1229 patients undergoing kidney transplant over an extend-
ed period (1972–2002) has reported the use of rATG to be higher in the
subpopulation who developed dnDSA (Table 3) but the difference was
lost on multivariate analysis, reﬂecting the selective use of rATG in pa-
tients at high risk (i.e. retransplant, PRA ≥15% or cold ischemia ≥36 h)
[4]. Kanter Berga et al. undertook a cross-sectional analysis of dnDSAoc-
currence based on single antigen ﬂow bead assay in 321 recipients of a
kidney transplant at standard immunological risk, and observed the use
of induction (either rATG or basiliximab) to be signiﬁcantly lower in the
patients who developed dnDSA versus those who remained non-
sensitized or developed non-DSA HLA antibodies (22.2% versus 54.5%
and 70%, p = 0.02), but data were not provided separately for rATG
and basiliximab [73].
One recent retrospective analysis has reviewed the development of
dnDSA in 196 non-sensitized patients undergoing heart transplantation
at a single center during 2006 to 2013 [74]. rATG inductionwas given at
a dose of 1.5 mg/kg for 3–5 days in 35 patients, with no induction in the
remaining patients. Maintenance therapy comprised tacrolimus, MMF
and steroids across the entire population. At one year, the proportion
of patients with de novo HLA antibody production was signiﬁcantly
lower in the subgroup treated with rATG (11% versus 21% in patients
without induction, p = 0.043) but dnDSA was similar (9% versus 12%,
p = 0.541). Imbalances between the two groups, and the relatively
short follow-up time, may have inﬂuenced the results.
4.1.1. Comparisons with other induction regimens
A recent observational analysis has compared the incidence of
dnDSA in 114 consecutive kidney transplant patients who received ei-
ther rATG or basiliximab induction, both with tacrolimus, MMF and ste-
roid maintenance therapy [71]. The patients were all moderately
sensitized: inclusion criteria were negative crossmatch on ﬂow cytom-
etry but DSA-positive using single antigen ﬂow bead testing (500 to
4000 mean ﬂuorescence intensity [MFI]). The desensitization protocol
comprised plasmapheresiswith IVIG, and rATG or basiliximab induction
was given according to physician preference. As might be expected, the
rATG group was at higher immunological risk, with signiﬁcantly higher
Table 2
rATG induction therapy in patients with or without dnDSA.
Study Study type/Time
period/Donor type
n Crossmatch
detection method
Induction/maintenance
immuno-suppression
Follow-up Induction type % rATG in
DSA+ patients
% rATG in
DSA- patients
P value
Huang
2012 [12]
Retrospective
2010–2011
Kidney or
kidney-pancreas
173 FC, mixed antigen
ﬂow beads + SAFB
CsA or TAC
MMF Steroids
480 days rATGa 80 67 0.30
BASa 0 12
No inductiona 20 21
Kanter Berga
2011 [33]
Retrospective
1997–2009
Deceased-donor
kidney
321 CDC, SAFB CsA or TAC
(otherwise
not speciﬁed)
Mean
62 months
rATG or BAS 22.2 54.5b 0.02
No induction
Cooper
2011 [8]
Retrospective
2007–2009
Kidney or
kidney-pancreas
244 FC + mixed antigen
ﬂow beads
TACa
MMFa
Steroidsa
2 years
rATG 66 66 0.73
BAS 6 4
No induction 28 30
Hourmant
2005 [4]
Retrospective
1972–2002
Kidney or
kidney-pancreas
1229 ELISA, CDC
and/or SAFB
Mixed 5 years rATG 72c 58 b0.001d
BAS, basiliximab; CDC, complement-dependent cytotoxicity; CsA, cyclosporine; DSA, donor-speciﬁc human leukocyte antibodies; FC, ﬂow cytometry;MMF,mycophenolatemofetil; rATG,
rabbit antithymocyte globulin; SAFB, single-antigen ﬂow beads; TAC, tacrolimus.
a 87% of patients received TAC/MMF/steroids.
b 70% in patients with non-donor speciﬁc HLA antibodies.
c 78% in patients with non-donor speciﬁc HLA antibodies
d Signiﬁcance was lost on multivariate analysis.
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sessions, and more IVIG injections compared to the basiliximab-treated
patients [71]. Despite this, after a follow-up of up to three years, rates of
dnDSA and ABMRwere both signiﬁcantly lower in the rATG-treated co-
hort based on Kaplan–Meier analyses (Fig. 1). Interestingly, the beneﬁt
for rATG appeared relatively late— after month 12. The beneﬁts of rATG
were conﬁrmed in a stepwise multivariate regression analysis, which
showed a hazard ratio (HR) of 0.16 for dnDSA and also for ABMR
when using rATG versus basiliximab (Table 3). For those patients who
did develop dnDSA, levels were strikingly lower with rATG (mean 455
MFI versus 3652 with basiliximab; p = 0.02). These results suggest
that rATG induction achieves a decrease in dnDSA production inmoder-
ately sensitized patients over the ﬁrst three years following kidney
transplantation compared to IL-2RA induction [71].
A randomized prospective pilot study by Ejaz et al. has compared
rates of dnDSA between kidney transplant patients receiving rATG
alone, or with the addition of rituximab, bortezomib or both rituximab
and bortezomib (the number of rATG doses was reduced according to
the concomitant therapy) [62]. The study population was at high risk,Table 3
dnDSA production in rATG-treated transplant patients.
Study Study type/Time period/
Donor type
n Crossmatch detection
method
Induction/maint
immuno-suppre
Brokhof
2014 [71]
Observational
2009–2011
Deceased-donor kidney
114 SAFB TAC
MMF
Steroids
Ejaz
2013 [62]
Prospective
Randomized
2008–2013
Kidney
40 CDC, FC, SAFB TAC
MMF
Steroids
Todeschini
2013 [72]
Retrospective
Matched cohort
Kidney
48 Mixed antigen
ﬂow beads
Low-dose sirolim
or low-dose CsA
MMF
Steroids to day 7
Delgado
2009 [70]
Prospective
First kidney transplant
37 CDC, mixed antigen
ﬂow beads + SAFB
TAC
MMF
± Steroids
ABMR, antibody-mediated rejection; BAS, basiliximab; CDC, complement-dependent cytotoxici
cyte antibodies; FC, ﬂow cytometry; HR, hazard ratio; MMF, mycophenolate mofetil; rATG, rab
a Multivariate analysis.selected on the basis of PRA ≥20% (or historical PRA ≥50%), T-cell or B-
cell positive crossmatch on ﬂow cytometry, or positive CDC crossmatch
with conﬁrmed DSA, or loss of a previous graft to acute rejection. Mainte-
nance immunosuppression comprised tacrolimus, MMF and steroids. At
the end of the one-year study, there was no difference in the rates of
dnDSA or ABMR between the four groups, although absolute numbers
were low (Table 3). Based on these initial data, addition of profound
naïve and memory B-cell depletion using rituximab, or plasma cell
apoptosis via bortezomib, does not appear to further inhibit dnDSA
production in sensitized kidney transplant patients given rATG induction,
although further data are required. In another comparative analysis,
Todeschini and colleagues undertook a retrospective study in which
they compared lymphocyte reconstitution and dnDSA in 16 kidney trans-
plant patients treatedwith alemtuzumab induction versus a matched co-
hort of 32 rATG-treated patients [72]. All patients were DSA-negative at
time of transplant, but by year 1 the incidence of dnDSAwas signiﬁcantly
lower in the rATG cohort (12.5% versus 50%, p = 0.01), a difference the
authors attributed to alemtuzumab-induced changes to B-cell pheno-
types, notably an expansion of naïve B-cells [72].enance
ssion
Follow-up Induction type % dnDSA at
last follow-up
% ABMR at
last follow-up
3 years rATG HR 0.16, 95%
CI 0.04–1.50,
p = 0.003 for
rATG vs BASa
HR 0.16, 95%
CI 0.05–0.60,
p = 0.006 for
rATG vs BASa
BAS
1 year rATG 30% p = 0.70 10% p = 0.36
rATG + rituximab 30% 0%
rATG + bortezomib 10% 30%
rATG + rituximab +
bortezomib
30% 10%
us 2 years Low-dose rATG +
BAS
12.5% p = 0.011 –
Alemtuzumab 50% –
≤5 years rATG + steroids 6.3% –
rATG no steroids 0% –
ty; CI, conﬁdence interval; CsA, cyclosporine; dnDSA, de novo donor-speciﬁc human leuko-
bit antithymocyte globulin; SAFB, single-antigen ﬂow beads; TAC, tacrolimus.
Fig. 1. (a) De novo donor speciﬁc antibodies [dnDSAs] and (b) antibody-mediated rejec-
tion [ABMR] during the ﬁrst three years after kidney transplantation in 114 moderately
sensitized patients in an observational study (Kaplan–Meier estimates). Adapted with
permission from Reference [71].
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There is currently intense interest in the prognostic importance of
preformed DSA and newly formed DSA after organ transplantation,
but undertaking trials to deﬁne the best immunosuppressive strategy
tominimize the risks associatedwith DSA is challenging. Controlled tri-
als of desensitization techniques are limited by ethical considerations
for a control arm and lack of agreement on suitable endpoints such as
DSA titers or histological changes. Evaluation of prevention of dnDSA
is less problematic, but is likely to be restricted to patients with at
least moderate sensitization to avoid unnecessary intervention. Com-
parative studies of immunosuppressive agents are now starting to rou-
tinely include baseline assessments of anti-HLA DSA status, and to
monitor DSA post-transplant, but in the meantime the transplant com-
munity is required tomake prescribing decisions based on the available,
imperfect evidence base.
Despite these caveats, rATG appears to inhibit DSA production. rATG
induction may be helpful in reducing the risk of ABMR in presensitized
kidney transplant patients with high-strength DSA. In patients with
low-strength preformed DSA, regimens including rATG induction have
been effective in avoiding ABMR and achieving good graft survival
rates. However, comparative data are lacking which makes it difﬁcult
to draw conclusions. Consistent with results from randomized trials
showing improved BPAR rates with rATG versus IL-2RA induction
[13,14] in high immunological risk kidney transplant recipients and, inone trial, improved graft survival versus no induction [15], rATG induc-
tion appears to reduce the risk of dnDSA and ABMR in moderately sen-
sitized patients compared to non-B-cell depleting IL2-RA induction
therapy [71].
Future studies of rATG could usefully include a protocol-deﬁned
schedule for DSAmonitoring tomonitor DSA recurrence after desensiti-
zation and occurrence of de novo DSA, with longer-term follow-up.
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